.png){kind=logo}
2022
Clinical cancer research
Praluzatamab ravtansine, a CD166-Targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial
Details
Authors:
Valentina Boni, Olga Vasiljeva
Title of the Article:
Praluzatamab ravtansine, a CD166-Targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial
Journal:
Clinical cancer research
Year of Publication:
2022
Pages:
2020-2029
Volume and Issue Number:
vol. 28, no. 10
ISSN Number:
1078-0432
DOI (Digital Object Identifier):
10.1158/1078-0432.CCR-21-3656
Researchers
References
Access paper
Access the PDF publication document.
More documentation
Related publications
Browse all publications
